##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 123 Download : 87

##plugins.themes.academic_pro.article.main##

Abstract

In this presented article, it was presented that 5-(p-Aminophenyl) - 1,3,4-oxadiazole-2-tion (conditionally D-111) at doses of 10, 30 and 60 mg / kg when administered orally to white mice with various analyzers, including strychnine (1.2 mg / kg subcutaneously), and also orally in doses of 10 and 30 mg/kg. the anticonvulsant activity of the substance and the comparative drug carbamazepines was studied using a model of convulsive seizure induced using repeated administration of corazole at a dose of 30 mg/kg.The anticonvulsant effects of the compound D-111, carbamazepine and control groups at various doses were studied. Based on the results obtained, the studied substance demonstrated high anticonvulsant activity in convulsive seizures, mainly on the strychnine convulsion model.

Keywords

Epilepsy corazole kidling oxadiazole-2-tion strychnine

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. https://doi.org/10.62480/tjms.2022.vol13.pp17-21
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. ILAE official report: a practical clinical definition of epilepsy / R.S. Fisher, C. Acevedo, A. Arzimanoglou et al. // Epilepsia. – 2014. – Vol. 55. – P. 475-482.
  2. Гордеева Л. Сложно, дорого, но возможно: Как сегодня лечат эпилепсию // Лекарственное обозрение. — 05/08/2014. — № 6.
  3. Hauser, W.A. First seizure definitions and worldwide incidence and mortality / W.A. Hauser, E. Beghi // Epilepsia. – 2008. – Vol. 49. – P. 8-12.
  4. Толмачев, П.А. Сравнителная характеристика заболеваемости эпилепсии в Российской Федерации на примере Кировского, Пензенского и Уляновского центров Приволжского Федерального Округа / П.А. Толмачев, Н.В. Наймушина [и др.] // Евразийское Научное Объединение. - 2017. - Т. 1. - №. 5. - С. 64-66.
  5. Fisher, Robert S.; Acevedo, Carlos; Arzimanoglou, Alexis; Bogacz, Alicia; Cross, J. Helen; Elger, Christian E.; Engel, Jerome; Forsgren, Lars; French, Jacqueline A.; Glynn, Mike; Hesdorffer, Dale C.; Lee, B.I.; Mathern, Gary W.; Moshé, Solomon L.; Perucca, Emilio; Scheffer, Ingrid E.; Tomson, Torbjörn; Watanabe, Masako; Wiebe, Samuel (2014). “ILAE Official Report: A practical clinical definition of epilepsy”. Epilepsia. Wiley. 55 (4): 475—482. DOI:10.1111/epi.12550. ISSN 0013-9580.
  6. Mattson R.H., Cramer J.A., Collins J.F. et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures / // N. Engl. J. Med. – 1985. – Vol. 313. – P. 145-151.
  7. Kwan, P. Drug treatment of epilepsy: when does it fail and how to optimize its use / P. Kwan, M.J. Brodie // CNS Spectr. – 2004. – Vol. 9. – P. 110- 119.
  8. French J.A., White H.S., Klitgaard H. et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities / // Epilepsia. – 2013. – Vol. 54. – P. 3-12.
  9. Wilcox K.S., Dixon-Salazar T., Sills G.J. et al. Issues related to development of new antiseizure treatments / // Epilepsia. – 2013. – Vol. 54. – P. 24-34.
  10. Kumar B, Kumar A, Beheraand AK, Raj V (2016) Latest Update on Pharmacological Activities of 1,3,4-Oxadiazole Derivatives. Journal of Cell Science & Therapy (2016) Volume 7, Issue 1 Ther 7:233.
  11. Ankit Siwach and Prabhakar Kumar Verma. Therapeutic potential of oxadiazole or furadiazole containing compounds. Siwach and Verma BMC Chemistry (2020) 14:70. Page.2-40. https://doi.org/10.1186/s13065-020-00721-2
  12. B. Ramana M, Mothilal M, M. Rao G, M.K. Murthy, Ravi Varala, H. Babu Bollikolla. Strategies to Synthesis of 1,3,4-Oxadiazole Derivatives and Their Biological Activities: A Mini Review. J. Chem. Rev., 2022, 4(3), 255-271. https://doi.org/10.22034/JCR.2022.341351.1170
  13. Ю.Р.Мирзаев, Н.В.Турсунова, Х.А.Расулова, З.И. Саноев. Особенности
  14. психофармакологической активности суммы фуранохинолиновых алкалоидов из Haplophyllum perforatum. ХЛ Международная научно-практическая конференция «Современная медицина: Актуальные вопросы. 2015, с.103-110.
  15. Sanoev Z.I., Mirzaev Yu.R. Pharmacological Activity Of The Possessing New Atypical Neuroleptics 1-Phenyltetrahydroisoquinoline Structure. The American Journal of Medical Sciences and Pharmaceutical Research Published: August 11, 2020 | Pages: 18-26 Doi: https://doi.org/10.37547/TAJMSPR/Volume02Issue08-03
  16. Sanoev Z.I., Mirzaev Yu.R. Research of a new atypical neuroleptic 1-(3,4,-methylenedioxyphenyl)- 6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline on the central nervous system. Annals of the Romanian Society for Cell Biology, 2021,25(2), 2363–2369
  17. Sanoev Z.I. Skimmianine - a promising antidepressant among furanoquinoline alkaloids. Journal of Biomedicine and Practice 2020, Special issue -2, pp.751-757
  18. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
  19. Sanoev Z.I., Mirzaev Yu.R. Influence of donaxine on physical and psychoemotional state of white mice at single and prolonged administration. «European Journal of Biomedical and Life Sciences» №4, 2016, s. 45-49
  20. Sanoev Z.I., Mirzaev Yu.R (2018). On comparative stimulating action on the cns of furanoquinoline alkaloids of skimmianine and amitriptyline //Yeuropean science review № 5–6, May–June, Vienna, p.189-192
  21. Sanoev Z.I., Khamroev T.T., Abdinazarov I.T., Sadikov A.Z., Rakhimboev S.D., Ras’hidov S.Z. Study of N-deacetylappaconitine (N-DAL) anticonvulsant action. Oriental Journal of Medicine and Pharmacology. 2022, Vol 2, p. 29-37
  22. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (d-361). International Journal of Medical Sciences and Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01
  23. Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. Част первая. — М.: Гриф и К, 2012. — 944 с.
  24. Стрелков Р.Б. Статистические таблитсе для ускоренной количественной отсенки фармакологического еффекта. Фармакология и токсикология 1986. №4 с.100-104.
  25. Khatoon, H. Evaluation of anticonvulsant and neuroprotective effects of camel milk in strychnine-induced seizure model / H. Khatoon, R. Najam, T. Mirza [et al.] // Asian Pacific Journal of Tropical Disease. – 2015. – Т. 5. – №. 10. – С. 817-820.
  26. Рыбалченко Т.Л., Штрыгол С.Ю., Георгиянц В.А. Определение спектра противосудорожного действия новых антиконвулсантов – производных 1,2,3-триазола и 1,3,4-оксадиазола. Серия Медицина. Фармация. 2014. № 11 (182). Выпуск 26/1. ст.199-203. УДК: 547.791.6:547.461.3:615.213

Most read articles by the same author(s)